Advertisement

Journal of Clinical Immunology

, Volume 35, Issue 1, pp 68–74 | Cite as

Invariant Natural Killer T Cells are Reduced in Hereditary Hemochromatosis Patients

  • M. L. Maia
  • C. S. Pereira
  • G. Melo
  • I. Pinheiro
  • M. A. Exley
  • G. Porto
  • M. F. Macedo
Original Research

Abstract

Purpose

Invariant natural killer T (iNKT) cells are CD1d restricted-T cells that react to lipid antigens. iNKT cells were shown to be important in infection, autoimmunity and tumor surveillance. Alterations in the number and function of these cells were described in several pathological conditions including autoimmune and/or liver diseases. CD1d is critical for antigen presentation to iNKT cells, and its expression is increased in liver diseases. The liver is the major organ affected in Hereditary Hemochromatosis (HH), an autosomal recessive disorder caused by excessive iron absorption. Herein, we describe the study of iNKT cells of HH patients.

Methods

Twenty-eight HH patients and 24 control subjects from Santo António Hospital, Porto, were included in this study. Patient’s iron biochemical parameters (serum transferrin saturation and ferritin levels) and the liver function marker alanine transaminase (ALT) were determined at the time of study. Peripheral blood iNKT cells were analyzed by flow cytometry using an anti-CD3 antibody and the CD1d tetramer loaded with PBS57.

Results

We found a decrease in the percentage and number of circulating iNKT cells from HH patients when compared with control population independently of age. iNKT cell defects were more pronounced in untreated patients, relating with serum ferritin and transferrin saturation levels. No correlation was found with ALT, a marker of active liver dysfunction.

Conclusions

Altogether, our results demonstrate that HH patients have reduced numbers of iNKT cells and that these are influenced by iron overload.

Keywords

Invariant natural killer T cells hereditary hemochromatosis iron lipid 

Notes

Acknowledgments

This work was supported by Fundação para a Ciência e a Tecnologia (PEST-C/SAU/LA0002/2013 - FCOMP-01-0124-FEDER-037277) and by FEDER Funds through the Operational Competitiveness Programme — COMPETE and by National Funds through FCT — Fundação para a Ciência e a Tecnologia under the project FCOMP-01-0124-FEDER-015955 (PTDC/SAU-ORG/110112/2009). MAE was partially supported by NIH grant CA170194. CSP was supported by a fellowship from Fundação para a Ciência e Tecnologia (SFRH/BD/79211/2011). The authors would like to thank the NIH Tetramer Core, Emory University, USA, for providing the CD1d-PBS57 tetramer.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010;11:197–206.PubMedCrossRefGoogle Scholar
  2. 2.
    Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11:131–42.PubMedCrossRefGoogle Scholar
  3. 3.
    De Libero G, Mori L. How the immune system detects lipid antigens. Prog Lipid Res. 2010;49:120–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Lynch L, O’Shea D, Winter DC, Geoghegan J, Doherty DG, O’Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol. 2009;39:1893–901.PubMedCrossRefGoogle Scholar
  5. 5.
    Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336:489–93.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Montoya CJ, Cataño JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol. 2008;127:1–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He X-S, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 2002;123:1031–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Lucas M, Gadola S, Meier U, Young NT, Harcourt G, Karadimitris A, et al. Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J Virol. 2003;77:2251–7.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Exley MA, Koziel MJ. To be or not to be NKT: natural killer T cells in the liver. Hepatology. 2004;40:1033–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002;109:131–40.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Driver JP, Scheuplein F, Chen Y-G, Grier AE, Wilson SB, Serreze DV. Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes. 2010;59:423–32.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001;100:144–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bollyky PL, Wilson SB. CD1d-restricted T-cell subsets and dendritic cell function in autoimmunity. Immunol. Cell Biol. 2004;307–14.Google Scholar
  14. 14.
    De Libero G, Collmann A, Mori L. The cellular and biochemical rules of lipid antigen presentation. Eur J Immunol. 2009;39:2648–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, et al. Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells. J Immunol. 2004;173:2159–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, et al. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol. 1997;159:1216–24.PubMedGoogle Scholar
  17. 17.
    Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology. 1993;80:561–5.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007;46:1291–301.PubMedCrossRefGoogle Scholar
  19. 19.
    Santos PCJL, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci. 2012;13:1497–511.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Gton CAW, Ley KVK. Review article: haemochromatosis. Aliment Pharmacol Ther. 2002;1963–75.Google Scholar
  21. 21.
    Porto G, Cardoso CS, Gordeuk V, Cruz E, Fraga J, Areias J, et al. Clinical and genetic heterogeneity in hereditary haemochromatosis: association between lymphocyte counts and expression of iron overload. Eur J Haematol. 2001;67:110–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Arosa FA, Oliveira L, Porto G, da Silva BM, Kruijer W, Veltman J, et al. Anomalies of the CD8+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8 + CD28- T cells. Clin Exp Immunol. 1997;107:548–54.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Porto B, Vieira R, Porto G. Increased capacity of lymphocytes from hereditary hemochromatosis patients homozygous for the C282Y HFE mutation to respond to the genotoxic effect of diepoxybutane. Mutat Res. 2009;673:37–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Cruz E, Vieira J, Almeida S, Lacerda R, Gartner A, Cardoso CS, et al. A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med Genet. 2006;7:16.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    De Sousa M, Porto G. The immunological system in hemochromatosis. J Hepatol. 1998;28 Suppl 1:1–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Macedo MF, Porto G, Costa M, Vieira CP, Rocha B, Cruz E. Low numbers of CD8+ T lymphocytes in hereditary haemochromatosis are explained by a decrease of the most mature CD8+ effector memory T cells. Clin Exp Immunol. 2010;159:363–71.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Jing Y, Gravenstein S, Chaganty NR, Chen N, Lyerly KH, Joyce S, et al. Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood. Exp Gerontol. 2007;42:719–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Peralbo E, DelaRosa O, Gayoso I, Pita ML, Tarazona R, Solana R. Decreased frequency and proliferative response of invariant Valpha24Vbeta11 natural killer T (iNKT) cells in healthy elderly. Biogerontology. 2006;7:483–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Reuben A, Phénix M, Santos MM, Lapointe R. The WT hemochromatosis protein HFE inhibits CD8+ T-lymphocyte activation. Eur J Immunol. 2014;44:1604–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Niemelä O, Parkkila S, Britton RS, Brunt E, Janney C, Bacon B. Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver injury. J Lab Clin Med. 1999;133:451–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Salio M, Silk JD, Cerundolo V. Recent advances in processing and presentation of CD1 bound lipid antigens. Curr Opin Immunol. 2010;22:81–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF. Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest. 1991;88:1207–15.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51:845–52.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol. 2002;97:1–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • M. L. Maia
    • 1
  • C. S. Pereira
    • 1
  • G. Melo
    • 2
  • I. Pinheiro
    • 1
  • M. A. Exley
    • 3
    • 4
  • G. Porto
    • 2
    • 5
  • M. F. Macedo
    • 1
    • 6
  1. 1.UniLiPeIBMC—Institute for Molecular and Cellular Biology, University PortoPortoPortugal
  2. 2.Clinical HematologyCHP-HSA—Santo António General Hospital PortoPortoPortugal
  3. 3.University of ManchesterManchesterUK
  4. 4.Brigham & Women’s HospitalHarvard Medical SchoolBostonUSA
  5. 5.BCRIB, IBMC—Institute for Molecular and Cellular Biology and ICBAS, Abel Salazar Institute for the Biomedical SciencesUniversity of PortoPortoPortugal
  6. 6.Aveiro Health Sciences ProgramUniversity of AveiroAveiroPortugal

Personalised recommendations